Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Lung Cancer

  Free Subscription


12.03.2018

2 Am J Clin Oncol
2 Am J Epidemiol
1 Am J Ind Med
1 Am J Respir Crit Care Med
1 Ann Oncol
4 Ann Thorac Surg
1 Anticancer Res
1 Arch Pathol Lab Med
7 BMC Cancer
2 Cancer Lett
1 Cancer Res
1 Chest
2 Clin Cancer Res
4 Clin Lung Cancer
4 Clin Nucl Med
1 Eur J Cardiothorac Surg
2 Int J Cancer
4 Int J Oncol
2 J Natl Cancer Inst
1 J Surg Oncol
2 J Thorac Oncol
7 Lancet Oncol
21 Lung Cancer
2 N Engl J Med
1 Nat Med
1 Oncogene
2 Oncol Rep
4 PLoS One
2 Science
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. NIHO S, Ikeda N, Michimae H, Suzuki K, et al
    Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Resear
    Am J Clin Oncol. 2018 Mar 7. doi: 10.1097/COC.0000000000000438.
    PubMed     Text format     Abstract available

  2. LAFUENTE-SANCHIS A, Estors-Guerrero M, Zuniga A, Martinez-Hernandez NJ, et al
    Clinical Significance of Molecular Micrometastasis in the Sentinel Lymph Node of Early-stage Non-Small Cell Lung Cancer Patients.
    Am J Clin Oncol. 2018 Mar 5. doi: 10.1097/COC.0000000000000432.
    PubMed     Text format     Abstract available


    Am J Epidemiol

  3. CHANG ET, Lau EC, Van Landingham C, Crump KS, et al
    Reanalysis of Diesel Engine Exhaust and Lung Cancer Mortality in the Diesel Exhaust in Miners Study (DEMS) Cohort Using Alternative Exposure Estimates and Radon Adjustment.
    Am J Epidemiol. 2018 Mar 7. pii: 4924566. doi: 10.1093.
    PubMed     Text format    

  4. SILVERMAN DT
    Invited Commentary: Diesel Exhaust and Lung Cancer Aftermath of Becoming an IARC Group 1 Carcinogen.
    Am J Epidemiol. 2018 Mar 7. pii: 4924564. doi: 10.1093.
    PubMed     Text format    


    Am J Ind Med

  5. BETANSEDI CO, Vaca Vasquez P, Counil E
    A comprehensive approach of the gender bias in occupational cancer epidemiology: A systematic review of lung cancer studies (2003-2014).
    Am J Ind Med. 2018 Mar 6. doi: 10.1002/ajim.22823.
    PubMed     Text format     Abstract available


    Am J Respir Crit Care Med

  6. BITON J, Ouakrim H, Dechartres A, Alifano M, et al
    Impaired Tumor-infiltrating T Cells in Patients with COPD Impacts Lung Cancer Response to PD-1 Blockade.
    Am J Respir Crit Care Med. 2018 Mar 8. doi: 10.1164/rccm.201706-1110.
    PubMed     Text format     Abstract available


    Ann Oncol

  7. BESSE B, Mazieres J, Ribassin-Majed L, Barlesi F, et al
    Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial.
    Ann Oncol. 2017;28:1078-1083.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  8. THOMAS DC, Arnold BN, Hoag JR, Salazar MC, et al
    Timing and Risk Factors Associated with Venous Thromboembolism Following Lung Cancer Resection.
    Ann Thorac Surg. 2018 Mar 1. pii: S0003-4975(18)30259.
    PubMed     Text format     Abstract available

  9. CATTANEO SM 2ND, Meisenberg BR, Geronimo MCM, Bhandari B, et al
    Lung Cancer Screening in the Community Setting.
    Ann Thorac Surg. 2018 Mar 1. pii: S0003-4975(18)30262.
    PubMed     Text format     Abstract available

  10. SEPESI B, Nelson DB, Mitchell KG, Gibbons DL, et al
    Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
    Ann Thorac Surg. 2018 Mar 3. pii: S0003-4975(18)30268.
    PubMed     Text format     Abstract available

  11. LU E, Colditz GA
    Thoracic Skeletal Muscle Is Associated with Adverse Outcomes after Lobectomy for Lung Cancer (Statistical Commentary).
    Ann Thorac Surg. 2018 Feb 28. pii: S0003-4975(18)30249.
    PubMed     Text format    


    Anticancer Res

  12. TOYOKAWA G, Yamada Y, Tagawa T, Kinoshita F, et al
    High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer.
    Anticancer Res. 2018;38:1821-1825.
    PubMed     Text format     Abstract available


    Arch Pathol Lab Med

  13. LOZANO MD, Echeveste JI, Abengozar M, Mejias LD, et al
    Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less.
    Arch Pathol Lab Med. 2018;142:291-298.
    PubMed     Text format     Abstract available


    BMC Cancer

  14. JIN BF, Yang F, Ying XM, Gong L, et al
    Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
    BMC Cancer. 2018;18:259.
    PubMed     Text format     Abstract available

  15. TAYLOR SA, Mallett S, Miles A, Beare S, et al
    Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and Streamline L).
    BMC Cancer. 2017;17:299.
    PubMed     Text format     Abstract available

  16. SHIMAZU K, Tada Y, Morinaga T, Shingyoji M, et al
    Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.
    BMC Cancer. 2017;17:309.
    PubMed     Text format     Abstract available

  17. SNEDDON S, Patch AM, Dick IM, Kazakoff S, et al
    Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma.
    BMC Cancer. 2017;17:396.
    PubMed     Text format     Abstract available

  18. IKEDA S, Kato T, Ogura T, Sekine A, et al
    Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thorac
    BMC Cancer. 2018;18:241.
    PubMed     Text format     Abstract available

  19. WANG G, Guo C, Zhao H, Pan Z, et al
    TIPE3 differentially modulates proliferation and migration of human non-small-cell lung cancer cells via distinct subcellular location.
    BMC Cancer. 2018;18:260.
    PubMed     Text format     Abstract available

  20. JOHNEN G, Gawrych K, Raiko I, Casjens S, et al
    Calretinin as a blood-based biomarker for mesothelioma.
    BMC Cancer. 2017;17:386.
    PubMed     Text format     Abstract available


    Cancer Lett

  21. ZHANG GN, Zhang YK, Wang YJ, Gupta P, et al
    Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo.
    Cancer Lett. 2018 Mar 5. pii: S0304-3835(18)30181.
    PubMed     Text format     Abstract available

  22. YANG YF, Lee YC, Lo S, Chung YN, et al
    A positive feedback loop of IL-17B-IL-17RB activates ERK/beta-catenin to promote lung cancer metastasis.
    Cancer Lett. 2018;422:44-55.
    PubMed     Text format     Abstract available


    Cancer Res

  23. MAKINOSHIMA H, Umemura S, Suzuki A, Nakanishi H, et al
    Metabolic determinants of sensitivity to phosphatidylinositol 3-kinase pathway inhibitor in small-cell lung carcinoma.
    Cancer Res. 2018 Feb 28. pii: 0008-5472.CAN-17-2109.
    PubMed     Text format     Abstract available


    Chest

  24. CHEN LL, Finan M, Mead E, Halpern NA, et al
    A Lung Cancer Patient With Respiratory Insufficiency and Hemodynamic Instability.
    Chest. 2018;153:e49-e52.
    PubMed     Text format    


    Clin Cancer Res

  25. CAPPUZZO F, Landi L
    HER2 deregulation in lung cancer: right time to adopt an orphan?
    Clin Cancer Res. 2018 Mar 1. pii: 1078-0432.CCR-18-0198.
    PubMed     Text format     Abstract available

  26. YANG Z, Yang N, Ou Q, Xiang Y, et al
    Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients.
    Clin Cancer Res. 2018 Mar 5. pii: 1078-0432.CCR-17-2310.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  27. ZHENG Y, Shi A, Wang W, Yu H, et al
    Posttreatment Immune Parameters Predict Cancer Control and Pneumonitis in Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Clin Lung Cancer. 2018 Jan 4. pii: S1525-7304(17)30351.
    PubMed     Text format     Abstract available

  28. BILFINGER TV, Albano D, Perwaiz M, Keresztes R, et al
    Survival Outcomes Among Lung Cancer Patients Treated Using a Multidisciplinary Team Approach.
    Clin Lung Cancer. 2018 Feb 1. pii: S1525-7304(18)30018.
    PubMed     Text format     Abstract available

  29. WU AJ, Garay E, Foster A, Hsu M, et al
    Definitive Radiotherapy for Local Recurrence of NSCLC After Surgery.
    Clin Lung Cancer. 2017;18:e161-e168.
    PubMed     Text format     Abstract available

  30. SUN V, Raz DJ, Ruel N, Chang W, et al
    A Multimedia Self-management Intervention to Prepare Cancer Patients and Family Caregivers for Lung Surgery and Postoperative Recovery.
    Clin Lung Cancer. 2017;18:e151-e159.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  31. LI ZG
    Solitary Choroidal Metastasis From Lung Adenocarcinoma on FDG PET/CT.
    Clin Nucl Med. 2017 Jun 24. doi: 10.1097/RLU.0000000000001738.
    PubMed     Text format     Abstract available

  32. SHARMA P, Dwary AD, Khan EM
    Serendipitous Discovery of Isolated Gastric Metastases From Adenocarcinoma of the Lung on Staging 18F-FDG PET-CT.
    Clin Nucl Med. 2017 Aug 12. doi: 10.1097/RLU.0000000000001784.
    PubMed     Text format     Abstract available

  33. CHENG J, Ou X, Ye Y
    Prominent Pulmonary Metastases Without Concurrent Intra-abdominal Metastasis in a Case of Ovarian Carcinoma.
    Clin Nucl Med. 2018 Mar 7. doi: 10.1097/RLU.0000000000002045.
    PubMed     Text format     Abstract available

  34. WANG W, Yuan L, Kan Y, Yang J, et al
    Oligometastatic Stomach Carcinoma From Lung Squamous Cell Carcinoma Detected by 18F-FDG PET/CT.
    Clin Nucl Med. 2017 Jul 17. doi: 10.1097/RLU.0000000000001761.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  35. VON MEYENFELDT EM, Marres GMH, van Thiel E, Damhuis RAM, et al
    Variation in length of hospital stay after lung cancer surgery in the Netherlands.
    Eur J Cardiothorac Surg. 2018 Mar 5. pii: 4921284. doi: 10.1093.
    PubMed     Text format     Abstract available


    Int J Cancer

  36. WANG Y, Wang C, Zhang J, Zhu M, et al
    Interaction analysis between germline susceptibility loci and somatic alterations in lung cancer.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31351.
    PubMed     Text format     Abstract available

  37. GAO Y, Yang J, Cai Y, Fu S, et al
    IFN-gamma-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31357.
    PubMed     Text format     Abstract available


    Int J Oncol

  38. YI L, Sun D, Han Q, Liu Z, et al
    Interferon regulatory factor 3 mediates Poly(I:C)-induced innate immune response and apoptosis in nonsmall cell lung cancer.
    Int J Oncol. 2018 Mar 5. doi: 10.3892/ijo.2018.4300.
    PubMed     Text format     Abstract available

  39. MAEDA M, Chen Y, Lee S, Kumagai-Takei N, et al
    Induction of IL-17 production from human peripheral blood CD4+ cells by asbestos exposure.
    Int J Oncol. 2017;50:2024-2032.
    PubMed     Text format     Abstract available

  40. LI Y, Miao L, Yu M, Shi M, et al
    alpha1-antitrypsin promotes lung adenocarcinoma metastasis through upregulating fibronectin expression.
    Int J Oncol. 2017;50:1955-1964.
    PubMed     Text format     Abstract available

  41. LU S, Dong Z
    Overexpression of secretory phospholipase A2-IIa supports cancer stem cell phenotype via HER/ERBB-elicited signaling in lung and prostate cancer cells.
    Int J Oncol. 2017 Apr 19. doi: 10.3892/ijo.2017.3964.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  42. SAMET JM
    Lung Cancer, Smoking, and Obesity: It's Complicated.
    J Natl Cancer Inst. 2018 Mar 6. pii: 4923351. doi: 10.1093.
    PubMed     Text format    

  43. YU D, Zheng W, Johansson M, Lan Q, et al
    Overall and Central Obesity and Risk of Lung Cancer: A Pooled Analysis.
    J Natl Cancer Inst. 2018 Mar 6. pii: 4923348. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Surg Oncol

  44. VODICKA J, Mukensnabl P, Vejvodova S, Spidlen V, et al
    A more sensitive detection of micrometastases of NSCLC in lymph nodes using the one-step nucleic acid amplification (OSNA) method.
    J Surg Oncol. 2018;117:163-170.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  45. SPIGEL DR, Reynolds C, Waterhouse D, Garon EB, et al
    Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    J Thorac Oncol. 2018 Mar 5. pii: S1556-0864(18)30176.
    PubMed     Text format     Abstract available

  46. TOYOOKA S, Okumura N, Nakamura H, Nakata M, et al
    A multi-center randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer.
    J Thorac Oncol. 2018 Mar 2. pii: S1556-0864(18)30168.
    PubMed     Text format     Abstract available


    Lancet Oncol

  47. BACH PB, Brawley OW, Silvestri GA
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e133-e134.
    PubMed     Text format    

  48. WU YL, Zhong WZ
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - Authors' reply.
    Lancet Oncol. 2018;19:e127.
    PubMed     Text format    

  49. MA JA, Jiang S, Hu C, Xie Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e125.
    PubMed     Text format    

  50. WU F, Liu X, Ma JA, Gao Y, et al
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e124.
    PubMed     Text format    

  51. FIELD JK, Heuvelmans MA, Devaraj A, Heussel CP, et al
    Low-dose CT for lung cancer screening - Authors' reply.
    Lancet Oncol. 2018;19:e135-e136.
    PubMed     Text format    

  52. RUANO-RAVINA A, Perez-Rios M, Casan-Clara P, Provencio-Pulla M, et al
    Low-dose CT for lung cancer screening.
    Lancet Oncol. 2018;19:e131-e132.
    PubMed     Text format    

  53. ROSELL R, Karachaliou N
    Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer.
    Lancet Oncol. 2018;19:e126.
    PubMed     Text format    


    Lung Cancer

  54. RASKIN J, Masrori P, Cant A, Snoeckx A, et al
    Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody.
    Lung Cancer. 2017;109:74-77.
    PubMed     Text format     Abstract available

  55. DURUISSEAUX M, Antoine M, Rabbe N, Rodenas A, et al
    Lepidic predominant adenocarcinoma and invasive mucinous adenocarcinoma of the lung exhibit specific mucin expression in relation with oncogenic drivers.
    Lung Cancer. 2017;109:92-100.
    PubMed     Text format     Abstract available

  56. LI J, Wang Z, Groen HJM, Zhao J, et al
    Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.
    Lung Cancer. 2018 Mar 1. pii: S0169-5002(18)30273.
    PubMed     Text format    

  57. OKAMOTO I, Morita S, Tashiro N, Imamura F, et al
    Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.
    Lung Cancer. 2018;117:14-19.
    PubMed     Text format     Abstract available

  58. YANG W, Qian F, Teng J, Wang H, et al
    Community-based lung cancer screening with low-dose CT in China: Results of the baseline screening.
    Lung Cancer. 2018;117:20-26.
    PubMed     Text format     Abstract available

  59. ARIYASU R, Nishikawa S, Uchibori K, Oh-Hara T, et al
    High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer.
    Lung Cancer. 2018;117:1-6.
    PubMed     Text format     Abstract available

  60. ZHANG B, Xu J, Zhang X, Gu P, et al
    Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
    Lung Cancer. 2018;117:27-31.
    PubMed     Text format     Abstract available

  61. SCULIER JP, Lafitte JJ, Berghmans T, Meert AP, et al
    A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
    Lung Cancer. 2018;117:32-37.
    PubMed     Text format     Abstract available

  62. SPIGEL DR, Hainsworth JD, Shipley DL, Mekhail TM, et al
    Amrubicin and carboplatin with pegfilgrastim in patients with extensive stage small cell lung cancer: A phase II trial of the Sarah Cannon Oncology Research Consortium.
    Lung Cancer. 2018;117:38-43.
    PubMed     Text format     Abstract available

  63. GERBER DE, Socinski MA, Neal JW, Wakelee HA, et al
    Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
    Lung Cancer. 2018;117:44-49.
    PubMed     Text format     Abstract available

  64. GADGEEL S, Goss G, Soria JC, Felip E, et al
    Evaluation of the VeriStrat((R)) serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.
    Lung Cancer. 2017;109:101-108.
    PubMed     Text format     Abstract available

  65. ITO J, Fujimoto D, Nakamura A, Nagano T, et al
    Aprepitant for refractory nivolumab-induced pruritus.
    Lung Cancer. 2017;109:58-61.
    PubMed     Text format     Abstract available

  66. YOTSUKURA M, Yasuda H, Shigenobu T, Kaseda K, et al
    Clinical and pathological characteristics of EGFR mutation in operable early-stage lung adenocarcinoma.
    Lung Cancer. 2017;109:45-51.
    PubMed     Text format     Abstract available

  67. UENAMI T, Hosono Y, Ishijima M, Kanazu M, et al
    Vitiligo in a patient with lung adenocarcinoma treated with nivolumab: A case report.
    Lung Cancer. 2017;109:42-44.
    PubMed     Text format     Abstract available

  68. DEARDEN S, Brown H, Jenkins S, Thress KS, et al
    EGFR T790M mutation testing within the osimertinib AURA Phase I study.
    Lung Cancer. 2017;109:9-13.
    PubMed     Text format     Abstract available

  69. ODA K, Kato K, Nakamura M, Jotatsu T, et al
    Surface marker profiles on lung lymphocytes may predict the mechanism of immune-mediated pneumonitis triggered by tumor-infiltrating lymphocytes in lung cancer patients treated with pembrolizumab.
    Lung Cancer. 2018 Feb 21. pii: S0169-5002(18)30269.
    PubMed     Text format    

  70. ZHANG L, Li J, Hu J, Li D, et al
    Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
    Lung Cancer. 2017;109:109-116.
    PubMed     Text format     Abstract available

  71. ZHU YJ, Zhang HB, Liu YH, Zhang FL, et al
    Quantitative cell-free circulating EGFR mutation concentration is correlated with tumor burden in advanced NSCLC patients.
    Lung Cancer. 2017;109:124-127.
    PubMed     Text format     Abstract available

  72. HERRERA-MARTINEZ AD, Gahete MD, Sanchez-Sanchez R, Salas RO, et al
    The components of somatostatin and ghrelin systems are altered in neuroendocrine lung carcinoids and associated to clinical-histological features.
    Lung Cancer. 2017;109:128-136.
    PubMed     Text format     Abstract available

  73. BOLAND JM, Wampfler JA, Yang P, Yi ES, et al
    Growth pattern-based grading of pulmonary adenocarcinoma-Analysis of 534 cases with comparison between observers and survival analysis.
    Lung Cancer. 2017;109:14-20.
    PubMed     Text format     Abstract available

  74. ZHANG L, Li S, Choi YL, Lee J, et al
    Systematic identification of cancer-related long noncoding RNAs and aberrant alternative splicing of quintuple-negative lung adenocarcinoma through RNA-Seq.
    Lung Cancer. 2017;109:21-27.
    PubMed     Text format     Abstract available


    N Engl J Med

  75. COPUR MD, Gauchan D, Ramaekers R
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:868.
    PubMed     Text format    

  76. SANTONI M, Battelli N, Buti S
    Durvalumab in Stage III Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;378:869.
    PubMed     Text format    


    Nat Med

  77. DARDAEI L, Wang HQ, Singh M, Fordjour P, et al
    SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
    Nat Med. 2018 Mar 5. pii: nm.4497. doi: 10.1038/nm.4497.
    PubMed     Text format     Abstract available


    Oncogene

  78. MEDER L, Konig K, Dietlein F, Macheleidt I, et al
    LIN28B enhanced tumorigenesis in an autochthonous KRAS(G12V)-driven lung carcinoma mouse model.
    Oncogene. 2018 Mar 5. pii: 10.1038/s41388-018-0158.
    PubMed     Text format     Abstract available


    Oncol Rep

  79. SEIKE M, Kim CH, Zou F, Noro R, et al
    AXL and GAS6 co-expression in lung adenocarcinoma as a prognostic classifier.
    Oncol Rep. 2017;37:3261-3269.
    PubMed     Text format     Abstract available

  80. XU W, Wu B, Fu L, Chen J, et al
    Comparison of three different methods for the detection of circulating tumor cells in mice with lung metastasis.
    Oncol Rep. 2017;37:3219-3226.
    PubMed     Text format     Abstract available


    PLoS One


  81. Correction: Modulation of Pathways Underlying Distinct Cell Death Mechanisms in Two Human Lung Cancer Cell Lines in Response to SN1 Methylating Agents Treatment.
    PLoS One. 2018;13:e0194257.
    PubMed     Text format     Abstract available

  82. CARVALHO S, Leijenaar RTH, Troost EGC, van Timmeren JE, et al
    18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC) - A prospective externally validated study.
    PLoS One. 2018;13:e0192859.
    PubMed     Text format     Abstract available

  83. MALEKI VAREKI S, Salim KY, Danter WR, Koropatnick J, et al
    Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
    PLoS One. 2018;13:e0191766.
    PubMed     Text format     Abstract available

  84. HAN Y, Kim HJ, Kong KA, Kim SJ, et al
    Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0191590.
    PubMed     Text format     Abstract available


    Science

  85. ENGBLOM C, Pfirschke C, Zilionis R, Da Silva Martins J, et al
    Osteoblasts remotely supply lung tumors with cancer-promoting SiglecF(high) neutrophils.
    Science. 2017;358.
    PubMed     Text format     Abstract available

  86. KLAEGER S, Heinzlmeir S, Wilhelm M, Polzer H, et al
    The target landscape of clinical kinase drugs.
    Science. 2017;358.
    PubMed     Text format     Abstract available


    Thorax

  87. MOLLER H, Coupland VH, Tataru D, Peake MD, et al
    Geographical variations in the use of cancer treatments are associated with survival of lung cancer patients.
    Thorax. 2018 Mar 6. pii: thoraxjnl-2017-210710.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: